Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study
J. Clin. Oncol 2021 May 04;[EPub Ahead of Print], CAM Stege, K Nasserinejad, E van der Spek, YM Bilgin, A Kentos, M Sohne, RJW van Kampen, I Ludwig, N Thielen, N Durdu-Rayman, NCHP de Graauw, NWCJ van de Donk, EGM de Waal, MC Vekemans, GJ Timmers, M van der Klift, S Soechit, PAF Geerts, MH Silbermann, M Oosterveld, IS Nijhof, P Sonneveld, SK Klein, MD Levin, S ZweegmanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.